Literature DB >> 10150832

Ocular manifestations of metabolic disorders.

F Iwata1, M I Kaiser-Kupfer.   

Abstract

Articles published during the past year on the ocular manifestations of metabolic diseases and related issues are reviewed. The focus is on clarifying the genetic or molecular basis of various metabolic disorders. Mutations of the P gene were reported in tyrosinase-positive oculocutaneous albinism and autosomal recessive ocular albinism, and were associated with a wide range of clinical phenotypes. This finding should aid in more accurate diagnosis and facilitate genetic counseling. There is no consensus but the horizontal supranuclear gaze palsy in Gaucher's disease may aid in subtyping. The report of a family with Morquio syndrome suggests that lenticular opacities should be considered as an additional finding in this syndrome. Patients with nephropathic cystinosis, which had been a fatal disease in childhood, are now surviving to adulthood. Serious ocular complications were described in adults.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 10150832     DOI: 10.1097/00055735-199412000-00013

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  3 in total

1.  Evaluation of topical cysteamine therapy in the CTNS(-/-) knockout mouse using in vivo confocal microscopy.

Authors:  Jennifer L Simpson; Chyong Jy Nien; Kevin J Flynn; James V Jester
Journal:  Mol Vis       Date:  2011-10-08       Impact factor: 2.367

2.  Quantitative in vivo and ex vivo confocal microscopy analysis of corneal cystine crystals in the Ctns knockout mouse.

Authors:  Jennifer Simpson; Chyong Jy Nien; Kevin Flynn; Brian Jester; Stephanie Cherqui; James Jester
Journal:  Mol Vis       Date:  2011-08-17       Impact factor: 2.367

3.  The significance of opthalmologic evaluation in the early diagnosis of inborn errors of metabolism: the Cretan experience.

Authors:  Daria P Tsagaraki; Athanasios E Evangeliou; Miltiadis Tsilimbaris; Martha G Spilioti; Eleni P Mihailidou; Christos Lionis; Ioannis Pallikaris
Journal:  BMC Ophthalmol       Date:  2002-04-11       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.